Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

ng on Day 1 of a 21-day cycle. The primary endpoint of this study is overall survival; the secondary endpoints include progression-free survival, overall response rate, duration of response and quality of life.

Pharmion has completed the Scientific Advice (SA) process with the European Medicines Agency (EMEA) and has reached Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the amrubicin Phase 3 SCLC study.

Interim findings from a Phase 2, multi-center clinical study of amrubicin in second-line sensitive SCLC patients provided encouraging initial results and informed the design of the pivotal study. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2007. Response data from 24 evaluable patients were analyzed, 15 treated with amrubicin and nine with topotecan. Of the 15 amrubicin-treated patients, 40 percent showed an objective tumor response, including two complete responses and four partial responses. All responses were confirmed. None of the nine topotecan patients showed a response to the drug. The median duration of progression free survival at the interim analysis was 4.1 months for amrubicin patients compared to 2.0 months for topotecan patients. Patients are being followed for overall survival. The major toxicity of amrubicin is myelosuppression, which is managed with standard supportive therapy and dose adjustments.

In addition to the Phase 2 study in second-line sensitive SCLC patients, Pharmion has two additional ongoing Phase 2 studies of amrubicin therapy for small cell lung cancer patients; one as single-agent therapy in patients refractory to first-line therapy; and one as single-agent or combination therapy with cisplatin versus cisplatin plus etoposide in previously untreated extensive stage patients.

"The Phase 2 studies in small cell lung cancer, in both sensitive and refractory patients, have thus far generated data f
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Richmond Pharmacology is ... with a worldwide reputation for excellence in clinical ... in peer reviewed medical journals. Its officers are ... in discussions about rules for transparency and publication ... http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is conducted ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com , a managed ... Mississippi, announced the launch of a newly redesigned  web ... Vans of America ( www.WCvans.com ). ... more customer friendly.   MobilityFreedom.com now provides an ...
... BRISBANE, Calif., July 18, 2011 SARcode Bioscience, ... completion of a $44 million Series B private ... Sofinnova Ventures and was augmented by the additional ... Partners and Clarus Venture Partners. ...
Cached Medicine Technology:HASCO Medical Announces New Redesigned Websites for Mobility Freedom and Wheelchair Vans of America 2SARcode Bioscience Completes $44 Million Series B Financing 2SARcode Bioscience Completes $44 Million Series B Financing 3SARcode Bioscience Completes $44 Million Series B Financing 4
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on ... Maryland legislature but which has not been signed to date ... HB 449 with overwhelming bipartisan support on April 10, ... law. This bill ensures that fracking is prohibited in Maryland ... danger of fracking to our water supplies and the air ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The American ... exciting events in June. They will hold a webinar ... and a two-day class on Classical Chinese Medicine. , ... 3, Dr. Steve Given, the Dean of Clinical Education, ... the new First Professional Doctorate program. ACTCM is currently ...
(Date:5/22/2015)... 22, 2015 Hundreds of federal ... of individuals who allegedly experienced serious internal bleeding ... to move forward in the U.S. District Court, ... Order dated May 4, 2015, the Court has ... electronically stored information. Among other things, the Order ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will likely ... pulmonary disorder (COPD) as the dominant companies like ... well as Germany’s Boehringer Ingelheim compete with each ... market payers, clinicians and patients be disposed to ... new ones? , In spite of recently approved ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... ... of jowls – those fleshy, droopy folds at the jaw line that typically ... important part of a facelifting procedure. The issue will be debated by ... Surgery (ASAPS), being held at the Gaylord National Hotel and Convention Center April ...
... attack healthy people, researchers say , THURSDAY, April 22 ... fungus recently discovered in Oregon may soon spread to ... people in Oregon have died after being infected with ... In the 21 Pacific Northwest cases analyzed by researchers, ...
... ... Times and ABC News 20/20 , ... New York, NY (Vocus) April 23, 2010 -- Selected from ... 20/20 are among winners receiving top honors in the 2010 Journalistic Achievement Awards. This ...
... ... automobile accidents. , ... NY (PRWEB) April 23, 2010 -- The number of highway deaths showed a significant decline ... highway for a summer vacation road trip or even a short drive across town, says ...
... ... loss program without dieting or physical exercise. The Inside Out Workout low-impact high-reward workout ... application called "Food Workout" is an interactive game used while eating; both new workout ... ...
... not destined to cause symptoms or death and therefore represent ... to unnecessary treatment and other harms, it is important to ... it, according to a review published online April 22 in ... H. Gilbert Welch, M.D. and William Black, M.D., of the ...
Cached Medicine News:Health News:Facial Rejuvenation and the Jowl: How Far Should We Go? 2Health News:Facial Rejuvenation and the Jowl: How Far Should We Go? 3Health News:Facial Rejuvenation and the Jowl: How Far Should We Go? 4Health News:The American Society for Aesthetic Plastic Surgery (ASAPS) Announces the 2010 Journalistic Achievement Award Winners, 2Health News:The American Society for Aesthetic Plastic Surgery (ASAPS) Announces the 2010 Journalistic Achievement Award Winners, 3Health News:U.S. and New York Car Accident Deaths Continue Steady Decline 2Health News:Food Psychology Coaches Launch New Weight Loss Program for Ultimate Life Fitness Results 2Health News:Food Psychology Coaches Launch New Weight Loss Program for Ultimate Life Fitness Results 3Health News:Magnitude of overdiagnosis in cancer indicates need for strategies to address the problem 2
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: